Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash & Current Investments: 2021-2024

Historic Cash & Current Investments for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $243.6 million.

  • Kiniksa Pharmaceuticals International's Cash & Current Investments rose 51.16% to $529.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 33.47%. This contributed to the annual value of $243.6 million for FY2024, which is 18.05% up from last year.
  • According to the latest figures from FY2024, Kiniksa Pharmaceuticals International's Cash & Current Investments is $243.6 million, which was up 18.05% from $206.4 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's 5-year Cash & Current Investments high stood at $243.6 million for FY2024, and its period low was $182.2 million during FY2021.
  • Its 3-year average for Cash & Current Investments is $213.5 million, with a median of $206.4 million in 2023.
  • Data for Kiniksa Pharmaceuticals International's Cash & Current Investments shows a peak YoY increased of 18.05% (in 2024) over the last 5 years.
  • Over the past 4 years, Kiniksa Pharmaceuticals International's Cash & Current Investments (Yearly) stood at $182.2 million in 2021, then increased by 4.61% to $190.6 million in 2022, then grew by 8.27% to $206.4 million in 2023, then increased by 18.05% to $243.6 million in 2024.